Convergence Investment Partners’s Biogen BIIB Stock Holding History

Convergence Investment Partners’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.04M	Buy	23,321 +9,764	+72%	+$1.87M	0.48%	76
2026 Q1	$2.49M	Buy	13,557 +1,401	+12%	+$258K	0.41%	75
2025 Q4	$2.14M	Buy	12,156 +2,573	+27%	+$420K	0.43%	70
2025 Q3	$1.34M	Buy	+9,583	New	+$1.3M	0.3%	120
2020 Q4	–	Sell	-4,118	Closed	-$1.17M	–	234
2020 Q3	$1.17M	Buy	4,118 +25	+0.6%	+$6.97K	0.41%	85
2020 Q2	$1.09M	Buy	4,093 +1,022	+33%	+$307K	0.38%	89
2020 Q1	$972K	Sell	3,071 -1,943	-39%	-$590K	0.43%	75
2019 Q4	$1.49M	Sell	5,014 -1,514	-23%	-$420K	0.42%	76
2019 Q3	$1.52M	Sell	6,528 -1,282	-16%	-$299K	0.42%	69
2019 Q2	$1.83M	Sell	7,810 -389	-5%	-$89.8K	0.44%	81
2019 Q1	$1.94M	Sell	8,199 -92	-1%	-$29K	0.42%	80
2018 Q4	$2.5M	Buy	8,291 +1,532	+23%	+$489K	0.57%	51
2018 Q3	$2.39M	Sell	6,759 -4,883	-42%	-$1.68M	0.49%	64
2018 Q2	$3.38M	Buy	11,642 +11,241	+2,803%	+$3.16M	0.47%	81
2018 Q1	$110K	Buy	+401	New	+$124K	0.01%	338
2015 Q3	–	Sell	-24,201	Closed	-$9.78M	–	345
2015 Q2	$9.78M	Buy	+24,201	New	+$9.71M	0.96%	13
2015 Q1	–	Sell	-10,247	Closed	-$3.48M	–	363
2014 Q4	$3.48M	Buy	10,247 +2,729	+36%	+$883K	0.47%	59
2014 Q3	$2.49M	Buy	+7,518	New	+$2.48M	0.34%	107

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Convergence Investment Partners's BIIB Position: Q2 2026 in Review

Convergence Investment Partners increased its Biogen (BIIB) stake by 72% in Q2 2026, buying an estimated $1.87M and bringing the position to 23,321 shares worth $5.04M. The position accounts for 0.48% of the portfolio, ranked #76.

Convergence Investment Partners first reported a position in BIIB in Q3 2014 and has held it in 18 quarters since. The position peaked at $9.78M in Q2 2015. 1,036 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Convergence Investment Partners held 23,321 shares of Biogen worth $5.04M as of Q2 2026.
Convergence Investment Partners bought 9,764 Biogen shares in Q2 2026, an estimated $1.87M.
Biogen made up 0.48% of Convergence Investment Partners's portfolio in Q2 2026, its #76 holding.
Convergence Investment Partners first reported a position in Biogen in Q3 2014 and has held it in 18 quarters since.
Convergence Investment Partners's Biogen position peaked at $9.78M in Q2 2015.
1,036 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Convergence Investment Partners's 13F filing for Q2 2026, filed 31 Jul 2026.